Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 121,100 shares, a growth of 285.7% from the November 30th total of 31,400 shares. Based on an average daily trading volume, of 61,300 shares, the days-to-cover ratio is currently 2.0 days.

Evaxion Biotech A/S Stock Performance

NASDAQ:EVAX traded up $0.21 during trading hours on Friday, reaching $1.06. The company had a trading volume of 8,476,896 shares, compared to its average volume of 267,984. The firm has a market cap of $6.22 million, a price-to-earnings ratio of -3.66 and a beta of -0.39. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. The firm’s 50 day moving average price is $1.76 and its 200-day moving average price is $2.55. Evaxion Biotech A/S has a 52 week low of $0.84 and a 52 week high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The firm had revenue of $3.02 million during the quarter, compared to analysts’ expectations of $0.19 million. On average, analysts forecast that Evaxion Biotech A/S will post -0.15 EPS for the current year.

Institutional Investors Weigh In On Evaxion Biotech A/S

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Armistice Capital LLC increased its holdings in Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 392,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Armistice Capital LLC owned 7.24% of Evaxion Biotech A/S worth $1,137,000 at the end of the most recent reporting period. 11.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a research report on Friday, November 1st.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.